Overview

• Semaglutide treatment in mice led to about a 10% loss of lean body mass, including a roughly 6% drop in skeletal muscle size.
• Non-skeletal tissues accounted for most mass loss, with the liver shrinking by nearly half its original volume.
• Testing showed some muscles lost force-generating capacity even when their size remained largely unchanged.
• Novo Nordisk highlighted a Wegovy sub-study showing concurrent reductions in fat and lean body mass but noted that clinical trials did not measure muscle strength.
• Investigators and clinicians emphasize the need for dedicated human trials to assess semaglutide’s impact on muscle function and organ health.